Hamilton, NJ (PRWEB) June 4, 2010
Chrono Therapeutics Inc. (Chrono), a privately held company that pioneers chrono therapeutic health care products, announced today that it has been awarded another United States patent to protect its chrono-pharmacological systems and applications.
Guy DiPierro, CEO of Chrono, noted that this new patent grant enhances Chrono’s exclusivity for what is believed to be the next revolutionary change in therapeutics-namely tailored chrono-pharmacological therapies. Mr DiPierro noted that this new patent grant also affirms the novelty of Chrono’s technology and believes it will considerably reduce any potential risk to the Chrono group.
About Chrono Therapeutics Inc. Intellectual Property (IP)
Chrono Therapeutics’ IP estate includes issued, allowed, and granted fundamental patents in several of the world’s major pharmaceutical markets. This IP protects Chrono’s chrono-pharmacological applications and non-invasive drug delivery systems. Additional patents are and will soon be pending worldwide.
About Chrono Therapeutics Inc.
Chrono Therapeutics Inc. is specialty pharmaceutical company developing novel therapeutic systems and methods to become the global leader in Chrono Therapeutic based drug products. The significant advantages of chrono therapeutic based therapies have now become widely recognized and are quickly coming to the forefront as the next major advance in treating indications. The company is applying its therapeutic expertise to develop these chrono therapeutic and tailored applications that seek to dramatically increase efficacy over traditional non-tailored applications while decreasing adverse side effects and accumulated tolerance. The company’s leadership with chrono therapeutic optimized application and methodologies and fundamental patents, technology, and know-how has proven key in forming major alliances with leading companies worldwide.
Chrono Therapeutics Inc.
Guy DiPierro, Chief Executive Officer